Reuters
01 Jun 2026, 10:34 UTC · 2h ago
Source · https://www.reuters.com/business/healthcare-pharmaceuticals/summit-rises-after-lung-cancer-drug-trial-shows-15-higher-survival-rate-than-2026-06-01/
Read source
Search tags
Story key points
2 claims · impact-rated
Summit Therapeutics' ivonescimab therapy showed a 15% improvement in overall survival for advanced lung cancer patients compared to BeOne Medicines' Tevimbra. — Superior survival data in a major oncology indication is a primary catalyst for stock price appreciation and potential market share dominance.
+0.80Summit Therapeutics' shares rose as much as 7% in pre-market trading following the data release. — Immediate positive price action confirms investor confidence and short-term bullish sentiment.
+0.30Ticker attribution
Model heads
Its immunotherapy drug Tevimbra was outperformed by a competitor's therapy in terms of patient survival.
Continue reading
6 related stories
Shares rose after clinical data showed its therapy helped patients live longer than a competitor's product.
Partner in the successful ivonescimab therapy trial results.
Impact vectors
5 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
Benzinga
9h ago
